Investor Site Visit

RNS Number : 8550R

Advanced Medical Solutions Grp PLC

10 November 2011

 



10 November 2011

Advanced Medical Solutions Group plc 

("AMS" or "the Company")

Investor site visit

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, will today be hosting a site visit at Winsford for a number of institutional investors.

No new trading or financial information will be disclosed during the visit.

-ends -

For further information, please visit www.admedsol.com or contact:

Advanced Medical Solutions Group plc

Chris Meredith, Chief Executive Officer                                                         Tel: [phone]

Mary Tavener, Finance Director

Tavistock Communications

John West / Chris Munden / Andrew Dunn                                                   Tel: [phone]

Investec Bank plc

Gary Clarence / Daniel Adams                                                                    Tel: [phone]

Notes to Editors:

About Advanced Medical Solutions Group plc - see www.admedsol.com

Founded in 1991, AMS is a leading company in the development and manufacture of innovative and technologically advanced products for the US$15 billion global wound care market. These products are sold in countries across the globe either directly or through a number of strategic partners and distributors.

AMS' advanced woundcare products are based on an extensive range of technologies including alginates, silver alginates and hydrophilic polyurethane foams. These and other products pioneer the concept of moist wound healing, allowing wounds to heal faster and with less pain and scarring. They protect the wound, deal with tissue fluids, provide an optimal environment for healing to occur and, in the case of silver alginates, include a safe and effective broad-spectrum anti-microbial agent for infection control.

AMS' wound closure and sealants products are based on cyanoacrylate adhesive ("superglue") technology developed for medical applications. Tissue adhesives offer significant benefits over conventional ways of closing wounds following trauma or surgical incision. They are simple to use, non-invasive, help to reduce the risk of infection, minimise trauma to the patient and provide good clinical and cosmetic outcomes. The technology is also ideally suited to protecting skin from breakdown or for use as a skin sealant to help prevent infection of surgical sites.

 

END

 

 

MSCEANFEFLLFFEF